Amino acid conjugates providing for sustained systemic concentrations of GABA analogues
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-031/195
C07C-229/28
출원번호
UP-0128225
(2008-05-28)
등록번호
US-7645797
(2010-02-22)
발명자
/ 주소
Gallop, Mark
Cundy, Kenneth C.
Scheuerman, Randall A.
Barrett, Ronald W.
Zerangue, Noa
출원인 / 주소
XenoPort, Inc.
대리인 / 주소
Miller, D. Byron
인용정보
피인용 횟수 :
0인용 특허 :
41
초록
Compounds that provide for sustained systemic concentrations of GABA analogs following oral administration to animals are disclosed. Pharmaceutical compositions including, and methods using, such compounds are also disclosed.
대표청구항▼
What is claimed is: 1. A compound having the formula and pharmaceutically acceptable salts thereof, wherein: D is a moiety selected from the group consisting of the following GABA analog moieties: R3 is a covalent bond; R11 is —COOH; and R56 is substituted arylalkyl; with the prov
What is claimed is: 1. A compound having the formula and pharmaceutically acceptable salts thereof, wherein: D is a moiety selected from the group consisting of the following GABA analog moieties: R3 is a covalent bond; R11 is —COOH; and R56 is substituted arylalkyl; with the proviso that R56 is not 4-bromophenylmethyl. 2. A compound having the formula and pharmaceutically acceptable salts thereof, wherein: D is a moiety selected from the group consisting of the following GABA analog moieties: R3 is a covalent bond; R11 is —COOH; and R56 is substituted arylalkyl; with the proviso that R56 is not 4-bromophenylmethyl; and provided that the compound has a half-life of at least 1 hour when incubated in vitro at 37° C. at a concentration of 5 μM with an S9 fraction of Caco-2 cell homogenate at a protein concentration of 0.5 mg/mL. 3. The compound of any one of claims 1 and 2, wherein R56 is selected from the group consisting of 2-methylphenylmethyl, 3-methylphenylmethyl, 4-methylphenylmethyl, 2-methoxyphenylmethyl, 3-methoxyphenylmethyl, 4-methoxyphenylmethyl, 2-trifluoromethylphenylmethyl, 3-trifluoromethylphenylmethyl, 4-trifluoromethylphenylmethyl, 2-cyanophenylmethyl, 3-cyanophenylmethyl, 4-cyanophenylmethyl, 2-fluorophenylmethyl, 3-fluorophenylmethyl, 4-fluorophenylmethyl, 2-chlorophenylmethyl, 3-chlorophenylmethyl, 4-chlorophenylmethyl, 2-bromophenylmethyl, 3-bromophenylmethyl, 2-iodophenylmethyl, 3-iodophenylmethyl, 4-iodophenylmethyl, 2,3-difluorophenylmethyl, 2,4-difluorophenylmethyl, 2,5-difluorophenylmethyl, 2,6-difluorophenylmethyl, 3,4-difluorophenylmethyl, 3,5-difluorophenylmethyl, 2,3-dichlorophenylmethyl, 2,4-dichlorophenylmethyl, 2,5-dichlorophenylmethyl, 2,6-dichlorophenylmethyl, 3,4-dichlorophenylmethyl, and 3,5-dichlorophenylmethyl. 4. The compound of any one of claims 1 and 2, wherein R56 is selected from 4-trifluorophenylmethyl, 4-cyanophenylmethyl, and 2,4-difluorophenylmethyl. 5. The compound of claim 1, which upon oral administration to a patient in need of therapy, provides therapeutically efficacious levels of a GABA analog in the plasma of the patient, where the GABA analog in the plasma of the patient has a concentration which over time provides a curve of concentration of the GABA analog in the plasma over time, the curve having an area under the curve (AUC) or a maximum plasma concentration (Cmax) which is substantially more proportional to the dose of GABA analog administered, as compared to the proportionality achieved following oral administration of the GABA analog itself. 6. The compound of claim 1, which is metabolized to produce a GABA analog at a sufficient rate in vivo, upon colonic administration to rats, to produce a Cmax or an AUC of the GABA analog in plasma of at least 200% of the Cmax or an AUC of the GABA analog in plasma achieved by colonically administering an equimolar dose of the GABA analog itself. 7. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to claim 1 and a pharmaceutically acceptable carrier. 8. An oral dosage form comprising: a sustained release oral dosage form containing a compound of claim 1, the dosage form being adapted for oral delivery to a patient; the dosage form further being adapted to release the compound gradually into the intestinal lumen of the patient over a period after oral administration. 9. The dosage form of claim 8, wherein the period comprises at least about 6 hours. 10. The dosage form of claim 8, wherein the dosage form releases from 0 to 20% of a compound in 0 to 2 hours, from 20 to 50% of the compound in 2 to 12 hours, from 50 to 85% of the compound in 3 to 20 hours and greater than 75% of the compound in 5 to 18 hours. 11. The dosage form of claim 8, wherein the dosage form comprises an osmotic dosage form, a compound-releasing polymer, a compound-releasing lipid, a compound-releasing wax, tiny timed-release pills, or compound-releasing beads. 12. A method for achieving sustained release of a GABA analog in a patient in need of therapy with the GABA analog, comprising orally administering to the patient a sustained release dosage form containing a therapeutically effective amount of the compound of claim 1. 13. A method for treating epilepsy, depression, anxiety, psychosis, or pain in a patient, comprising administering to a patient in need of such treatment a therapeutically effective amount of the oral dosage form of claim 8. 14. The method of claim 13 wherein R56 is selected from the group consisting of 2-methylphenylmethyl, 3-methylphenylmethyl, 4-methylphenylmethyl, 2-methoxyphenylmethyl, 3-methoxyphenylmethyl, 4-methoxyphenylmethyl, 2-triflurormethylphenylmethyl, 3-trifluoromethylphenylmethyl, 4-trifluoromethylphenylmethyl, 2-cyanophenylmethyl, 3-cyanophenylmethyl, 4-cyanophenylmethyl, 2-fluorophenylmethyl, 3-fluorophenylmethyl, 4-fluorophenylmethyl, 2-chlorophenylmethyl, 3-chlorophenylmethyl, 4-chlorophenylmethyl, 2-bromophenylmethyl, 3-bromophenylmethyl, 2-iodophenylmethyl, 3-iodophenylmethyl, 4-iodophenylmethyl, 2,3-difluorophenylmethyl, 2,4-difluorophenylmethyl, 2,5-difluorophenylmethyl, 2,6-difluorophenylmethyl, 3,4-difluorophenylmethyl, 3,5-difluorophenylmethyl, 2,3-dichlorophenylmethyl, 2,4-dichlorophenylmethyl, 2,5-dichlorophenylmethyl, 2,6-dichlorophenylmethyl, 3,4-dichlorophenylmethyl, and 3,5-dichlorophenylmethyl.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (41)
Gallop,Mark; Cundy,Kenneth C.; Scheuerman,Randall A.; Barrett,Ronald W.; Zerangue,Noa, Amino acid conjugates providing for sustained systemic concentrations of GABA analogues.
Urquhart John (Palo Alto CA) Theeuwes Felix (Los Altos CA), Delivery system comprising means for shielding a multiplicity of reservoirs in selected environment of use.
Ayer Atul D. (Palo Alto CA) Swanson David R. (Palo Alto CA) Kuczynski Anthony L. (Palo Alto CA), Dosage form for treating cardiovascular diseases comprising isradipine.
Richard B. Silverman ; Ryszard Andruszkiewicz PL; Po-Wai Yuen ; Denis Martin Sobieray ; Lloyd Charles Franklin ; Mark Alan Schwindt, GABA and L-glutamic acid analogs for antiseizure treatment.
Silverman Richard B. (Morton Grove IL) Andruszkiewicz Ryszard (Sopot PLX) Yuen Po-Wai (Ann Arbor MI) Sobieray Denis M. (Holland MI) Franklin Lloyd C. (Hamilton MI) Schwindt Mark A. (Holland MI), GABA and L-glutamic acid analogs for antiseizure treatment.
Silverman Richard B. ; Andruszkiewicz Ryszard,PLX ; Yuen Po-Wai ; Sobieray Denis Martin ; Franklin Lloyd Charles ; Schwindt Mark Alan, GABA and L-glutamic acid analogs for antiseizure treatment.
Silverman Richard B. ; Andruszkiewicz Ryszard,PLX ; Yuen Po-Wai ; Sobieray Denis Martin ; Franklin Lloyd Charles ; Schwindt Mark Alan, GABA and L-glutamic acid analogs for antiseizure treatment.
Silverman Richard B. ; Andruszkiewicz Ryszard,PLX ; Yuen Po-Wai ; Sobieray Denis Martin ; Franklin Lloyd Charles ; Schwindt Mark Alan, GABA and L-glutamic acid analogs for antiseizure treatment.
Nabil Farah FR; Philippe Barthelemy FR; Joseph Joachim FR, Process for the manufacture of pharmaceutical composition with modified release of active principle comprising the matrix.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.